Krystal L Tomei1, Christine Y Mau2, Michael Ghali3, Jayoung Pak4, Ira M Goldstein5. 1. University Hospitals Case Medical Center, Rainbow Babies and Children's Hospital, Cleveland, OH, USA. 2. Department of Neurological Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. 3. Department of General Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. 4. Department of Neurology, Rutgers New Jersey Medical School Newark, Newark, NJ, USA. 5. Department of Neurological Surgery, Rutgers New Jersey Medical School, 90 Bergen Street, Suite 8100, Newark, NJ, 07101-1709, USA. goldstir@njms.rutgers.edu.
Abstract
BACKGROUND: We describe three children with Angelman syndrome and medically refractory epilepsy. METHODS: Case series of three pediatric patients with Angelman syndrome and medically refractory epilepsy. All three patients failed medical treatment and were recommended for vagal nerve stimulator (VNS) implantation. RESULTS: Following VNS implantation, all three patients experienced reduction in seizure frequency greater than that afforded by medication alone. CONCLUSION: We present vagal nerve stimulator implantation as a viable treatment option for medically refractory epilepsy associated with Angelman syndrome.
BACKGROUND: We describe three children with Angelman syndrome and medically refractory epilepsy. METHODS: Case series of three pediatric patients with Angelman syndrome and medically refractory epilepsy. All three patients failed medical treatment and were recommended for vagal nerve stimulator (VNS) implantation. RESULTS: Following VNS implantation, all three patients experienced reduction in seizure frequency greater than that afforded by medication alone. CONCLUSION: We present vagal nerve stimulator implantation as a viable treatment option for medically refractory epilepsy associated with Angelman syndrome.